DOI QR코드

DOI QR Code

The Study and Measurement of Three Dimensional Spatial Dose Rate from Radioiodine Therapy

고용량 옥소 치료 시 3차원적 공간선량률 측정 및 연구

  • Chang, Boseok (Department of Image Information Engineering, Pusan National University)
  • 장보석 (부산대학교 공과대학 영상정보공학과)
  • Received : 2013.05.13
  • Accepted : 2013.06.21
  • Published : 2013.06.30

Abstract

Spatial dose rates of high dose $^{131}I$ therapy patients were Measured Three dimensional (X, Y, Z) distributions. I have constructed geometrical an aluminum support structure for spatial dose meters placed in 5 different heights, 8 different azimuthal angles, 6 different time interval and distance 100 cm from High dose$^{131}I$ therapy patients. when the height of vertical plane Spatial dose distribution is 100 cm, the Spatial dose rates is max and the error range is low. the vertical plane Spatial dose rates was found to be 71.85 ${\mu}Sv/h$ on the average at a distance of 100 cm, height 100 cm, from the patients 24 hours after $^{131}I$ oral administration. I divided 12 patients into two groups. I have analysed group A (drinking 5 L water) and group B (drinking 3 L water) in order to measure decrease spatial dose rates. I have found the spatial distributions of patient dose rates is $44.9{\pm}7.2$ ${\mu}Sv/h$ in group A and $100.3{\pm}8.1$ ${\mu}Sv/h$ in group B by 24 after $^{131}I$ oral administration. the reduction factor was found to be approximately 54 % through drinking 5 L water during 24 hours.

고용량 옥소 치료 시 수평면, 수직면, 방위각에 따라 3차원적으로 방출되는 공간선량률을 측정하였다. 정확한 측정을 위해 기하학적 구조의 알루미늄 틀을 제작하여 100 cm 거리에서, 높이 (5 측정점), 방위각 (8 측정점), 시간적 간격 (6 측정점)을 각각 나누어서 분석하였다. 수직면상 공간선량률 분포는 $^{131}I$을 경구 투여 24 시간 후 환자로부터 거리 100 cm, 높이 100 cm 지점에서 환자군 평균 71.85 ${\mu}Sv/h$로 가장 높았다. 수분섭취를 통한 공간선량률 감쇠 정도를 두 그룹으로 나누어 실험하였다. $^{131}I$을 경구 투여 24시간 뒤 거리 100 cm, 높이 100 cm에서 공간선량률 분포가 A 실험군은 44.9 ${\mu}Sv/h$이고 B 실험군은 100.28 ${\mu}Sv/h$이다. A 실험군이 B 실험군과 비교하여 고용량 옥소 치료 시 수분섭취 정도에 따라 약 53 %의 피폭경감 효과를 확인하였다.

Keywords

References

  1. Health insurance Review & Assesment service of Korea. statistical data. 2010
  2. Harbert JC. Radioiodine therapy of differentiated thyroid carcinoma. Nuclear Medical therapy. New York Thiem Medical Publishers p.36-90, 1987
  3. ICRP: Recommendations of the international commission on Radiological Protection,ICRP Publication 26, Pergamon Press, Oxford, New York, 1977
  4. Goldsmith SJ, Malblant JC, Nuclear Oncology. Philadelphia Lippincott Williams & Wilkin, pp.195-220. 2001
  5. Lubin, E. Definitive improment in the approach to the treated patient as a radioactive source. J Nucl Med, Vol 43, No. 3, pp 364-5, Mar 2002
  6. Siegel JA, Marcus CS, Sparks RB. Calculating the absorbed dose from radioactive patients: the line source versus point source model. J Nucl Med Vol. 43, No. 9, pp 124-4, 2002
  7. Gui-Won Lee. Minimized Radiation dose of patients receiving high dose radioiodine therapy. JKRS, Vol. 30. No. 4, pp 435-442, 2007
  8. C.G Kim, Are Medical personnel safe from radiation exposure from patient receiving radioiodine ablation therapy. Nucl Med Mol Imaging Vol. 43. No. 4, Aug 2009
  9. B.S Chang, S.H Kim, J.K Ahn., Radiation dose rate PET-scan patients injection with F-18-FDG, NPSM, Vol. 62, No. 12, pp. 1345-1350, December 2010.
  10. M. Elschot et al, The influence of self-absorption on pet/ct shielding requirements, J Med. Phys Vol. 37, No 6, pp. 2999-3007, June 2010. https://doi.org/10.1118/1.3432618
  11. Korea Atomic Energy Research Institute, Certificate for Detector Calibration, 2013
  12. ICRP Publication 94, Release of patients after therapy with unsealed radionuclides, pp 53-58, Ann. ICRP 34 (2), 200